Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group.
Jara-Sánchez C, Martín M, García-Sáenz JA, Barnada A, Fernández-Aramburo A, López-Vega JM, Pelegrí A, Alba E, Casado A; Spanish Group for Research in Breast Cancer. Jara-Sánchez C, et al. Among authors: alba e. Clin Breast Cancer. 2003 Feb;3(6):399-404. doi: 10.3816/cbc.2003.n.004. Clin Breast Cancer. 2003. PMID: 12636884 Clinical Trial.
Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.
Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, De La Haba J, Tres A, Alvarez I, Alba E, Arcusa A, Oltra A, Batista N, Checa T, Perez-Carrion R, Curto J; GEICAM Group. Pico C, et al. Among authors: alba e. Ann Oncol. 2004 Jan;15(1):79-87. doi: 10.1093/annonc/mdh016. Ann Oncol. 2004. PMID: 14679124 Free article. Clinical Trial.
Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).
Colomer R, Viñas G, Beltran M, Izquierdo A, Lluch A, Llombart-Cussac A, Alba E, Munárriz B, Martín M; Spanish Breast Cancer Research Group. Colomer R, et al. Among authors: alba e. J Clin Oncol. 2004 Mar 1;22(5):961-2. doi: 10.1200/JCO.2004.99.143. J Clin Oncol. 2004. PMID: 14990656 No abstract available.
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group. Alba E, et al. J Clin Oncol. 2004 Jul 1;22(13):2587-93. doi: 10.1200/JCO.2004.08.125. J Clin Oncol. 2004. PMID: 15226326 Clinical Trial.
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, Schneider J, Martínez del Prado P, Alba E, Fernández-Aramburo A. Jara Sánchez C, et al. Among authors: alba e. Breast Cancer Res Treat. 2007 Jan;101(2):215-23. doi: 10.1007/s10549-006-9282-0. Epub 2006 Jul 6. Breast Cancer Res Treat. 2007. PMID: 16823507
330 results